Market Summary
Myocardial Ischemia Market Overview
The Myocardial Ischemia Market Size was valued at USD 1.2 Billion in 2023. The Global Myocardial Ischemia industry is projected to grow from USD 1.3 Billion in 2024 to USD 1.5 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.50% during the forecast period (2024 - 2032). Myocardial ischemia is a medical condition characterized by the insufficient blood flow to the heart muscle via coronary arteries, commonly resulting in chest pain. Myocardial ischemia is a medical condition characterized by the insufficient blood flow to the heart muscle via coronary arteries, commonly resulting in chest pain.
Factors such as the high prevalence of coronary heart disease, rising incidence of diabetes, and lifestyle changes provide suitable backgrounds for the development of market growth. However, the high cost of therapeutic surgeries and side effects related to medications are projected to restrain the market growth during the forecast period.
Myocardial Ischemia Market Dynamics
Myocardial ischemia is a common occurrence and occurs with increased frequency in patients with diabetes due to cardiac autonomic dysfunction. According to a study published in the Endocrinology, Diabetes & Metabolism Case Reports journal in 2013, ~22% of the patients diagnosed with type 2 diabetes were estimated to suffer from Silent Myocardial Ischemia (SMI). Moreover, it is reported that the prevalence of diabetes has increased.
This is illustrative by the fact sheet of the World Health Organization (WHO) published in 2017. According to it, the global prevalence of diabetes among individuals ages 18 years or more was about 8.5% in 2014. Thus, it is interpreted that the rising prevalence of diabetes provides a necessary driving force for the myocardial ischemia market to expand.
Myocardial Ischemia Market Segmentation
The myocardial ischemia market has been segmented into type, treatment & diagnosis, and end user. By type, the market has been bifurcated into symptomatic and asymptomatic.
Based on treatment & diagnosis, the market has been divided into diagnosis and treatment. Diagnosis segment has been further segregated into imaging and stress test.
The treatment has been further divided into medications and surgery. By end-user, the market has been classified as hospitals & clinics, diagnostic centers, ambulatory surgery centers, and others. The hospitals and clinics accounted for a market value of USD 18,744.2 million in 2023.
Myocardial Ischemia Market Key Players
The prominent players in the myocardial ischemia market are:
- Taxus Cardium (US)
- ViroMed Co. Ltd. (Republic of Korea )
- Edward Lifesciences (US)
- Daiichi Sankyo Company Limited (Japan)
- Boston Scientific Corporation (US)
- Merck KGaA (Germany)
- Novartis AG (Switzerland)
- Boehringer Ingelheim International GmbH (Germany)
- Johnson & Johnson Services Inc. (US)
- Bayer AG (Germany)
- AstraZeneca (UK)
Some of the key strategies followed by the players operating in the myocardial ischemia market were innovation, product development, acquisition, and expansion.
Myocardial Ischemia Market Regional Analysis
The myocardial ischemia market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is estimated to dominate the brain ischemia ischemiamarket during the forecast period. Americas accounts for the largest regional market owing to the rising prevalence of diabetes, obesity, physical inactivity, and excessive alcohol use among the population.
The European market for myocardial ischemia is expected to be the second-largest during the forecast period. The high growth rate is due to the high incidence rate of cardiovascular diseases in Europe. According to the European Cardiovascular Disease Statistics 2017, 45% of deaths in Europe is due to cardiovascular diseases (CVD).
Additionally, the companies operating in the market are mainly focusing on mergers and acquisition, which is expected to support market growth. Asia-Pacific is estimated to be the fastest-growing market due to the rising prevalence of diabetes. According to the Asian Diabetes Prevention Initiative, 60% of the world’s diabetic patient live in Asia. Such high incidences of diabetes that lead to silent myocardial ischemia are likely to fuel the market growth.
Moreover, in the Asia-Pacific region, China accounted for a market share of 23.5% in 2017. However, the Middle East and Africa are expected to observe slow growth due to less exposure to healthcare services and stringent government rules and regulations.
Key Updates
- In July 2016, Angionetics Inc., a subsidiary of Taxus Cardium, entered into an agreement with Huapont Life Sciences covering a USD 3,000,000 investment, to support the Generx Phase 3 clinical and commercialization development program.
- In February 2018, Edwards Lifesciences Corporation received the CE Mark for its self-expanding CENTERA valve, thus enhancing its transcatheter heart valve therapy segment.
- In August 2017, Boehringer Ingelheim Pharmaceuticals, Inc. received FDA approval for CyltezoTM (adalimumab-adbm).
Market Segmentation
Myocardial Ischemia Market, by Type
- Symptomatic
- Asymptomatic
Myocardial Ischemia Market, by Treatment & Diagnosis
- Diagnosis
- Treatment
Myocardial Ischemia Market, by End User
- Hospitals & Clinics
- Diagnostic Centres
- Ambulatory Surgery Centres
Myocardial Ischemia Market, by Region
- Americas
- North America
- US
- Canada
- North America
- Latin America
- Europe
- Western Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Western Europe
- Western Europe
- Eastern Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- Republic of Korea
- Rest of Asia-Pacific
- Middle East & Africa
- United Arab Emirates
- Saudi Arabia
- Oman
- Kuwait
- Qatar
- Rest of The Middle East & Africa
Available Additional Customizations
- Regulatory scenario
Intended Audience
-
- Medical device manufacturers and distributors
- Government research organizations
- Hospitals and clinics
- Regulatory agencies
- Pharmaceutical companies
Market Size & Forecast
|
Report Attribute/Metric |
Details |
|
Market Size 2023 |
1.2 (USD Billion) |
|
Market Size 2024 |
1.3 (USD Billion) |
|
Market Size 2032 |
1.5 (USD Billion) |
|
Compound Annual Growth Rate (CAGR) |
7.5 % (2024 - 2032) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Base Year |
2023 |
|
Market Forecast Period |
2024 - 2032 |
|
Historical Data |
2019 - 2023 |
| Forecast Units | Value (USD Billion) |
| Segments Covered | Type, Application, and End-User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Taxus Cardium, ViroMed Co. Ltd., Edward Lifesciences, Daiichi Sankyo Company Limited, Boston Scientific Corporation, Merck KGaA, Novartis AG, Boehringer Ingelheim International GmbH, Johnson & Johnson Services Inc., Bayer AG, AstraZeneca |
| Key Market Opportunities | Increasing prevalence of diabetes, rising incidence of cardiovascular diseases, government support, and growing healthcare investments |
| Key Market Drivers | High incidence of myocardial ischemia, increasing diagnostic applications, and advancements in medical technologies |
Leave a Comment